Fresenius Medical Care AG (NYSE:FMS) Shares Sold by Signaturefd LLC

Signaturefd LLC reduced its stake in shares of Fresenius Medical Care AG (NYSE:FMS) by 11.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,643 shares of the company’s stock after selling 958 shares during the quarter. Signaturefd LLC’s holdings in Fresenius Medical Care were worth $159,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Pacer Advisors Inc. raised its stake in Fresenius Medical Care by 14,252.1% during the 4th quarter. Pacer Advisors Inc. now owns 488,401 shares of the company’s stock worth $10,173,000 after acquiring an additional 484,998 shares in the last quarter. Envestnet Asset Management Inc. grew its position in Fresenius Medical Care by 362.2% during the 3rd quarter. Envestnet Asset Management Inc. now owns 259,033 shares of the company’s stock worth $5,580,000 after purchasing an additional 202,991 shares during the last quarter. O Shaughnessy Asset Management LLC grew its position in Fresenius Medical Care by 259.5% during the 3rd quarter. O Shaughnessy Asset Management LLC now owns 92,635 shares of the company’s stock worth $1,995,000 after purchasing an additional 66,864 shares during the last quarter. Uncommon Cents Investing LLC grew its position in Fresenius Medical Care by 19.7% during the 4th quarter. Uncommon Cents Investing LLC now owns 35,920 shares of the company’s stock worth $748,000 after purchasing an additional 5,900 shares during the last quarter. Finally, QRG Capital Management Inc. purchased a new position in Fresenius Medical Care during the 3rd quarter worth $676,000. 8.25% of the stock is currently owned by institutional investors and hedge funds.

Fresenius Medical Care Stock Down 0.5 %

FMS stock opened at $20.10 on Monday. The company has a market cap of $11.80 billion, a P/E ratio of 21.85, a P/E/G ratio of 1.10 and a beta of 1.00. Fresenius Medical Care AG has a 52 week low of $16.37 and a 52 week high of $27.72. The company’s 50-day moving average price is $19.51 and its 200 day moving average price is $19.47. The company has a current ratio of 1.42, a quick ratio of 1.07 and a debt-to-equity ratio of 0.47.

Fresenius Medical Care (NYSE:FMS) last released its quarterly earnings data on Tuesday, February 20th. The company reported $0.47 EPS for the quarter, topping analysts’ consensus estimates of $0.36 by $0.11. The firm had revenue of $5.37 billion for the quarter, compared to the consensus estimate of $5.32 billion. Fresenius Medical Care had a net margin of 2.56% and a return on equity of 4.99%. On average, research analysts expect that Fresenius Medical Care AG will post 1.51 earnings per share for the current fiscal year.

Fresenius Medical Care Cuts Dividend

The business also recently disclosed an annual dividend, which will be paid on Monday, June 3rd. Investors of record on Monday, May 20th will be issued a dividend of $0.437 per share. This represents a yield of 2.35%. The ex-dividend date is Friday, May 17th. Fresenius Medical Care’s dividend payout ratio is currently 46.74%.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on FMS. StockNews.com began coverage on shares of Fresenius Medical Care in a research report on Friday. They set a “strong-buy” rating on the stock. Morgan Stanley downgraded shares of Fresenius Medical Care from an “equal weight” rating to an “underweight” rating in a research report on Monday, January 8th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, two have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $32.25.

Fresenius Medical Care Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.